Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

HIV-associated neurocognitive disorder, extracellular vesicles and gender: vive la difference?

Brew BJ, Paul R.

AIDS. 2019 Sep 1;33(11):1795-1796. doi: 10.1097/QAD.0000000000002273. No abstract available.

PMID:
31356256
2.

Imaging correlates of the Blood Brain Barrier disruption in HIV associated neurocognitive disorder and therapeutic implications.

Chaganti J, Marripudi K, Staub LP, Rae CD, Gates TM, Moffat KJ, Brew BJ.

AIDS. 2019 Jul 2. doi: 10.1097/QAD.0000000000002300. [Epub ahead of print]

PMID:
31274535
3.

Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau.

Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, Brew BJ, Guillemin GJ, Lovejoy DB.

Neurobiol Aging. 2019 Aug;80:11-20. doi: 10.1016/j.neurobiolaging.2019.03.015. Epub 2019 Apr 1.

PMID:
31055163
4.

Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm.

Cysique LA, Brew BJ.

J Neurovirol. 2019 Jan 11. doi: 10.1007/s13365-018-0706-5. [Epub ahead of print]

PMID:
30635846
5.

HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction.

Asahchop EL, Branton WG, Krishnan A, Chen PA, Yang D, Kong L, Zochodne DW, Brew BJ, Gill MJ, Power C.

JCI Insight. 2018 Dec 6;3(23). pii: 122450. doi: 10.1172/jci.insight.122450.

6.

HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infection.

Cysique LA, Jugé L, Lennon MJ, Gates TM, Jones SP, Lovelace MD, Rae CD, Johnson TP, Nath A, Brew BJ.

AIDS. 2019 Mar 1;33(3):433-441. doi: 10.1097/QAD.0000000000002076.

PMID:
30475266
7.

Human Immunodeficiency Virus and the Nervous System.

Sutherland EJ, Brew BJ.

Neurol Clin. 2018 Nov;36(4):751-765. doi: 10.1016/j.ncl.2018.07.002. Review.

PMID:
30366553
8.

Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection.

Nichols MJ, Gates TM, Soares JR, Moffat KJ, Rae CD, Brew BJ, Cysique LA.

AIDS. 2019 Jan 27;33(1):55-66. doi: 10.1097/QAD.0000000000002042.

PMID:
30325766
9.

Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing.

Wilson MR, O'Donovan BD, Gelfand JM, Sample HA, Chow FC, Betjemann JP, Shah MP, Richie MB, Gorman MP, Hajj-Ali RA, Calabrese LH, Zorn KC, Chow ED, Greenlee JE, Blum JH, Green G, Khan LM, Banerji D, Langelier C, Bryson-Cahn C, Harrington W, Lingappa JR, Shanbhag NM, Green AJ, Brew BJ, Soldatos A, Strnad L, Doernberg SB, Jay CA, Douglas V, Josephson SA, DeRisi JL.

JAMA Neurol. 2018 Aug 1;75(8):947-955. doi: 10.1001/jamaneurol.2018.0463.

10.

HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau.

Anderson AM, Croteau D, Ellis RJ, Rosario D, Potter M, Guillemin GJ, Brew BJ, Woods SP, Letendre SL.

J Neuroimmunol. 2018 Jun 15;319:13-18. doi: 10.1016/j.jneuroim.2018.03.007. Epub 2018 Mar 18.

11.

Preface.

Brew BJ.

Handb Clin Neurol. 2018;152:xi. doi: 10.1016/B978-0-444-63849-6.09988-6. No abstract available.

PMID:
29604989
12.

HIV-associated neurocognitive disorder.

Smail RC, Brew BJ.

Handb Clin Neurol. 2018;152:75-97. doi: 10.1016/B978-0-444-63849-6.00007-4. Review.

PMID:
29604986
13.

Neurologic sequelae of primary HIV infection.

Brew BJ, Garber JY.

Handb Clin Neurol. 2018;152:65-74. doi: 10.1016/B978-0-444-63849-6.00006-2. Review.

PMID:
29604985
14.

Progressive multifocal leukoencephalopathy.

Zhai S, Brew BJ.

Handb Clin Neurol. 2018;152:123-137. doi: 10.1016/B978-0-444-63849-6.00010-4. Review.

PMID:
29604971
15.

Introduction to HIV infection and HIV neurology.

Brew BJ.

Handb Clin Neurol. 2018;152:1-2. doi: 10.1016/B978-0-444-63849-6.00001-3.

PMID:
29604969
16.

Effect of the Mediterranean diet on cognition and brain morphology and function: a systematic review of randomized controlled trials.

Radd-Vagenas S, Duffy SL, Naismith SL, Brew BJ, Flood VM, Fiatarone Singh MA.

Am J Clin Nutr. 2018 Mar 1;107(3):389-404. doi: 10.1093/ajcn/nqx070.

PMID:
29566197
17.

The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy.

Bundell C, Brunt SJ, Cysique LA, Brusch A, Brew BJ, Price P.

Pathology. 2018 Apr;50(3):313-316. doi: 10.1016/j.pathol.2017.10.017. Epub 2018 Feb 17.

PMID:
29463387
18.

No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Wright EJ, Grund B, Robertson KR, Cysique L, Brew BJ, Collins GL, Poehlman-Roediger M, Vjecha MJ, Penalva de Oliveira AC, Standridge B, Carey C, Avihingsanon A, Florence E, Lundgren JD, Arenas-Pinto A, Mueller NJ, Winston A, Nsubuga MS, Lal L, Price RW; INSIGHT START Neurology Substudy Group.

AIDS. 2018 May 15;32(8):985-997. doi: 10.1097/QAD.0000000000001778.

19.

Covertly active and progressing neurochemical abnormalities in suppressed HIV infection.

Cysique LA, Jugé L, Gates T, Tobia M, Moffat K, Brew BJ, Rae C.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 3;5(1):e430. doi: 10.1212/NXI.0000000000000430. eCollection 2018 Jan.

20.

Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.

Cysique LA, Soares JR, Geng G, Scarpetta M, Moffat K, Green M, Brew BJ, Henry RG, Rae C.

J Neurovirol. 2017 Aug;23(4):548-549. doi: 10.1007/s13365-017-0542-z. No abstract available.

PMID:
28755142
21.

Does HIV prematurely age the brain?

Brew BJ, Cysique L.

Lancet HIV. 2017 Sep;4(9):e380-e381. doi: 10.1016/S2352-3018(17)30108-X. Epub 2017 Jul 14. No abstract available.

PMID:
28716544
22.

Functional Connectivity in Virally Suppressed Patients with HIV-Associated Neurocognitive Disorder: A Resting-State Analysis.

Chaganti JR, Heinecke A, Gates TM, Moffat KJ, Brew BJ.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1623-1629. doi: 10.3174/ajnr.A5246. Epub 2017 Jun 8.

23.

Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis.

Warhurst S, Rofe CJ, Brew BJ, Bateson D, McGeechan K, Merki-Feld GS, Garrick R, Tomlinson SE.

Cephalalgia. 2018 Apr;38(4):754-764. doi: 10.1177/0333102417710636. Epub 2017 May 29.

24.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

25.

Bcl11b-A Critical Neurodevelopmental Transcription Factor-Roles in Health and Disease.

Lennon MJ, Jones SP, Lovelace MD, Guillemin GJ, Brew BJ.

Front Cell Neurosci. 2017 Mar 29;11:89. doi: 10.3389/fncel.2017.00089. eCollection 2017. Review.

26.

White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration.

Cysique LA, Soares JR, Geng G, Scarpetta M, Moffat K, Green M, Brew BJ, Henry RG, Rae C.

J Neurovirol. 2017 Aug;23(4):539-547. doi: 10.1007/s13365-017-0524-1. Epub 2017 Mar 21. Erratum in: J Neurovirol. 2017 Jul 28;:.

PMID:
28324319
27.

Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.

Kamminga J, Lal L, Wright EJ, Bloch M, Brew BJ, Cysique LA.

Curr HIV/AIDS Rep. 2017 Jun;14(3):83-92. doi: 10.1007/s11904-017-0349-9. Review.

PMID:
28284004
28.

Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity.

Gott C, Gates T, Dermody N, Brew BJ, Cysique LA.

PLoS One. 2017 Mar 6;12(3):e0171887. doi: 10.1371/journal.pone.0171887. eCollection 2017.

29.

Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.

Lim CK, Bilgin A, Lovejoy DB, Tan V, Bustamante S, Taylor BV, Bessede A, Brew BJ, Guillemin GJ.

Sci Rep. 2017 Feb 3;7:41473. doi: 10.1038/srep41473.

30.

Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.

Kamminga J, Bloch M, Vincent T, Carberry A, Brew BJ, Cysique LA.

J Clin Exp Neuropsychol. 2017 Oct;39(8):753-767. doi: 10.1080/13803395.2016.1263282. Epub 2017 Jan 4.

PMID:
28052738
31.

Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV.

Anesten B, Yilmaz A, Hagberg L, Zetterberg H, Nilsson S, Brew BJ, Fuchs D, Price RW, Gisslén M.

Neurol Neuroimmunol Neuroinflamm. 2016 Nov 9;3(6):e300. eCollection 2016 Dec.

32.

Has HIV-associated neurocognitive disorders now transformed into vascular cognitive impairment?

Brew BJ.

AIDS. 2016 Sep 24;30(15):2379-80. doi: 10.1097/QAD.0000000000001225. No abstract available.

PMID:
27603161
33.

Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis.

Lovelace MD, Varney B, Sundaram G, Franco NF, Ng ML, Pai S, Lim CK, Guillemin GJ, Brew BJ.

Front Immunol. 2016 Aug 4;7:246. doi: 10.3389/fimmu.2016.00246. eCollection 2016. Review.

34.

Characterization of the Kynurenine Pathway in CD8+ Human Primary Monocyte-Derived Dendritic Cells.

Braidy N, Rossez H, Lim CK, Jugder BE, Brew BJ, Guillemin GJ.

Neurotox Res. 2016 Nov;30(4):620-632. Epub 2016 Aug 10.

PMID:
27510585
35.

Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.

Lee JM, Tan V, Lovejoy D, Braidy N, Rowe DB, Brew BJ, Guillemin GJ.

Neuropharmacology. 2017 Jan;112(Pt B):346-364. doi: 10.1016/j.neuropharm.2016.05.011. Epub 2016 Jun 3. Review.

PMID:
27265569
36.

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.

Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, Guillemin GJ, Brew BJ.

Neuropharmacology. 2017 Jan;112(Pt B):373-388. doi: 10.1016/j.neuropharm.2016.03.024. Epub 2016 Mar 16. Review.

PMID:
26995730
37.

Strategies to target HIV-1 in the central nervous system.

Gray LR, Brew BJ, Churchill MJ.

Curr Opin HIV AIDS. 2016 Jul;11(4):371-5. doi: 10.1097/COH.0000000000000278. Review.

PMID:
26945147
38.

Short Communication: Do Cytomegalovirus Antibody Levels Associate with Age-Related Syndromes in HIV Patients Stable on Antiretroviral Therapy?

Brunt SJ, Cysique LA, Lee S, Burrows S, Brew BJ, Price P.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):567-72. doi: 10.1089/AID.2015.0328. Epub 2016 Mar 16.

PMID:
26876416
39.

Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ.

AIDS. 2016 Feb 20;30(4):591-600. doi: 10.1097/QAD.0000000000000951.

PMID:
26825032
40.

Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials.

Mayo NE, Brouillette MJ, Fellows LK; Positive Brain Health Now Investigators.

BMC Neurol. 2016 Jan 14;16:8. doi: 10.1186/s12883-016-0527-1.

41.

Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals.

Crossley KM, Agnihotri S, Chaganti J, Rodriguez ML, McNally LP, Venna N, Turbett SE, Gutman M, Morey A, Koralnik IJ, Brew BJ.

J Neurovirol. 2016 Aug;22(4):541-5. doi: 10.1007/s13365-015-0419-y. Epub 2016 Jan 4.

42.

Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?

Lennon MJ, Jones SP, Lovelace MD, Guillemin GJ, Brew BJ.

Neurotox Res. 2016 Feb;29(2):201-7. doi: 10.1007/s12640-015-9573-5. Epub 2015 Nov 12. Review.

PMID:
26563995
43.

The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults.

Cysique LA, Dermody N, Carr A, Brew BJ, Teesson M.

J Neurovirol. 2016 Feb;22(1):56-65. doi: 10.1007/s13365-015-0368-5. Epub 2015 Aug 25.

PMID:
26304840
44.

CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies.

Gray LR, Cowley D, Welsh C, Lu HK, Brew BJ, Lewin SR, Wesselingh SL, Gorry PR, Churchill MJ.

Mol Psychiatry. 2016 Apr;21(4):574-84. doi: 10.1038/mp.2015.111. Epub 2015 Aug 25.

45.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
46.

Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease.

Jones SP, Franco NF, Varney B, Sundaram G, Brown DA, de Bie J, Lim CK, Guillemin GJ, Brew BJ.

PLoS One. 2015 Jun 26;10(6):e0131389. doi: 10.1371/journal.pone.0131389. eCollection 2015.

47.

Consensus guidelines for the investigation and management of encephalitis.

Britton PN, Eastwood K, Brew BJ, Nagree Y, Jones CA.

Med J Aust. 2015 Jun 15;202(11):576-7. No abstract available.

PMID:
26068688
48.

Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand.

Britton PN, Eastwood K, Paterson B, Durrheim DN, Dale RC, Cheng AC, Kenedi C, Brew BJ, Burrow J, Nagree Y, Leman P, Smith DW, Read K, Booy R, Jones CA; Australasian Society of Infectious Diseases (ASID); Australasian College of Emergency Medicine (ACEM); Australian and New Zealand Association of Neurologists (ANZAN); Public Health Association of Australia (PHAA).

Intern Med J. 2015 May;45(5):563-76. doi: 10.1111/imj.12749. Review.

PMID:
25955462
49.

APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.

Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.

BMC Neurol. 2015 Apr 1;15:51. doi: 10.1186/s12883-015-0298-0.

50.

The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication.

Fois AF, Brew BJ.

Curr HIV/AIDS Rep. 2015 Jun;12(2):299-303. doi: 10.1007/s11904-015-0257-9. Review.

PMID:
25869939

Supplemental Content

Loading ...
Support Center